Erratum to: Oncol Ther DOI 10.1007/s40487-016-0016-0
The author of the above mentioned paper have noticed a mistake in Table 1 following publication and wish to make the following correction.
The reference for the lapatinib study should be 36 (Stacchiotti S, Tamborini E, Lo Vullo S, et al. Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol. 2013;24:1931–6), and the reference for the 9-nitro-camptothecin study should be 43 (Chugh R, Dunn R, Zalupski MM, et al. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol. 2005;23:3597–604).
Anzeige
The corrected Table 1 can be found below.
Table 1
Summary of systemic therapy data
Therapy | Target | Number of chordoma patients | Reported results | Study design | References |
|---|---|---|---|---|---|
Imatinib | PDGFR | 50 | 1 PR (RECIST); 35 SD; median PFS = 9 months (RECIST) | Single-arm phase II trial | Stacchiotti et al. [32] |
Imatinib | PDGFR | 17 | 0 PR; 17 SD | Case series | Ferraresi et al. [33] |
Lapatinib | EGFR | 18 | 13 SD; 6 PR (Choi); 0 PR (RECIST); median PFS = 8 months (RECIST) | Single-arm phase II trial | Stacchiotti et al. [36] |
Erlotinib | EGFR | 1 | 1 PR | Case report | Singhal et al. [37] |
Erlotinib + bevacizumab | EGFR, VEGF | 3 | 3 SD | Case report | Asklund et al. [38] |
Cetuximab + gefitinib | EGFR | 1 | 1 PR | Case report | Hof et al. [39] |
Cetuximab + gefitinib | EGFR | 1 | 1 PR | Case report | Linden et al. [40] |
Sorafenib | Multiple | 27 | 1 PR (RECIST); 9-month PFS = 73.0%; 12-month OS = 86.5% | Single-arm phase II trial | Bompas et al. [41] |
9-Nitro-camptothecin | Topoisomerase I | 15 | 1 PR (RECIST); median PFS = 9.9 months | Single-arm phase II trial | Chugh et al. [43] |
Thalidomide | Multiple | 1 | 1 PR | Case report | Chay et al. [44] |
GI-6301 (recombinant yeast-brachyury vaccine) | Brachyury | 11 | 1 PR (RECIST); 1 mixed response (RECIST); median PFS = 8.3 months | Phase I trial | Heery et al. [65] |
Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.